Sivik Global Healthcare’s Top Biotech Stock Picks For Q4

#3 Celgene Corporation (NASDAQ:CELG)

Shares Owned by Sivik Global Healthcare (as of September 30): 50,000 shares

Value of Holding (as of September 30): $5.409 Million

Moving on, during the third quarter Sivik Global Healthcare increased its stake in Celgene Corporation (NASDAQ:CELG) by 25% or 10,300 shares. Shares of the company have dropped by 8.2% in the last two trading sessions alone after it reported its fiscal 2015 third quarter results and currently is trading with meager year-to-date gains of 4.86%. Although the EPS of $1.23 on revenue of $2.33 billion that the company reported for the quarter was better than the EPS of $0.97 on revenue of $1.96 billion that it had reported for the same quarter last year, it wasn’t in-tune with the EPS of $1.22 on revenue of $2.40 billion that analysts had expected. Following the earnings release, On November 6, analysts at Canaccord Genuity reiterated their ‘Buy’ rating on the stock, but lowered their price target on it to $156 from $190. Cliff Asness‘ AQR Capital Management had increased its stake in Celgene Corporation (NASDAQ:CELG) by 21% or over 1.5 million shares during the April-June period.

#2 Amgen, Inc. (NASDAQ:AMGN)

Shares Owned by Sivik Global Healthcare (as of September 30): 40,000 shares

Value of Holding (as of September 30): $5.533 Million

Although shares of Amgen, Inc. (NASDAQ:AMGN) have remained flat for most part of 2015, it seems Sivik Global Healthcare believes that it is ready for a bull run and that’s why initiated a stake in the company during the third quarter. On November 8, Amgen, Inc. (NASDAQ:AMGN) and Cytokinetics, Inc. (NASDAQ:CYTK) announced favorable data from the  Phase 2 trial of the expansion phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). The company came out with better than expected fiscal 2015 third quarter earnings on October 28. While analysts had expected it to report EPS of $2.38 on revenue of $5.32 billion for the quarter, the company declared EPS of $2.72 on revenue of $5.72 billion. With an ownership of 9 million shares Billionaire Dan Loeb‘s Third Point was the largest shareholder of the company at the end of June among the funds we cover.

#1 Biogen Inc (NASDAQ:BIIB)

Shares Owned by Sivik Global Healthcare (as of September 30): 20,000 shares

Value of Holding (as of September 30): $5.836 Million

Finally, even though its stock suffered a massive 27.75% decline during the third quarter and Sivik Global Healthcare sold 4,800 shares of the company during the same period, Biogen Inc (NASDAQ:BIIB) remained the fund’s top biotech pick at the end of the third quarter. On October 21, the same day that the company released its fiscal 2015 third quarter results, it also announced that it would be laying off 880 of its employees, including 440 in its home state of Massachusetts. For the third quarter ending September 30, the company reported EPS of $4.48 on revenue of $2.39 billion versus analysts’ expectation of EPS of $3.80 on revenue of $2.65 billion. On November 5, analysts at Piper Jaffray upgraded the stock to ‘Overweight’ from ‘Neutral’. Andreas Halvorsen‘s Viking Global had initiated a stake in Biogen Inc during the second quarter by acquiring 513,444 shares of the company.

Disclosure: None